ERBB2 and breast cancer: Furthermore, MutL deficiency (connected with mismatch repair system alteration) represents a mutation related to endocrine treatment resistance, which appears in 15–17% of estrogen-receptor positive (ER+)/HER2-negative BC cases [85,88,89].